Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

References

• Agarwal S, Sane R, Ohlfest JR, et al. (2011). The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336:223–33.
   PubMed Web of Science ®Google Scholar
• Allard E, Hindre F, Passirani C, et al. (2008). 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. Eur J Nucl Med Mol Imaging 35:1838–46.
   PubMed Web of Science ®Google Scholar
• Allard E, Huynh NT, Vessières A, et al. (2009). Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model. Int J Pharm 379:317–23.
   PubMed Web of Science ®Google Scholar
• Allard E, Jarnet D, Vessières A, et al. (2010). Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft. Pharm Res 27:56–64.
   PubMed Web of Science ®Google Scholar
• Andre JB, Nagpal S, Hippe DS, et al. (2015). Cerebral blood flow changes in glioblastoma patients undergoing bevacizumab treatment are seen in both tumor and normal brain. Neuroradiol J 28:112–9.
   PubMed Web of Science ®Google Scholar
• Balzeau J, Pinier M, Berges R, et al. (2013). The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells. Biomaterials 34:3381–9.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gerstner ER, Emblem KE, et al. (2013). Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110:19059–64.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95.
   PubMed Web of Science ®Google Scholar
• Béduneau A, Saulnier P, Benoit JP. (2007). Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947–67.
   PubMed Web of Science ®Google Scholar
• Benizri S, Ferey L, Alies B, et al. (2018). Nucleoside-lipid-based nanocarriers for sorafenib delivery. Nanoscale Res Lett 13:17
   PubMed Web of Science ®Google Scholar
• Bondì ML, Botto C, Amore E, et al. (2015). Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells. Int J Pharm 493:75–85.
   PubMed Web of Science ®Google Scholar
• Boucher Y, Leunig M, Jain RK. (1996). Tumor angiogenesis and interstitial hypertension. Cancer Res 56:4264–6.
   PubMed Web of Science ®Google Scholar
• Brose MS, Frenette CT, Keefe SM, et al. (2014). Management of sorafenib-related adverse events: a clinician's perspective. Semin Oncol 41:S1–S16.
   PubMedGoogle Scholar
• Carra E, Barbieri F, Marubbi D, et al. (2013). Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle Georget. Tex 12:491–500.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Boucher Y, et al. (2011). Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2:281–98.
   PubMed Web of Science ®Google Scholar
• Chen R, Cohen AL, Colman H. (2016). Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr Treat Options Oncol 17:42
   PubMed Web of Science ®Google Scholar
• Cikankowitz A, Clavreul A, Tétaud C, et al. (2017). Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model. J Neurooncol 131:49–58.
   PubMed Web of Science ®Google Scholar
• Clavreul A, Pourbaghi-Masouleh M, Roger E, et al. (2017). Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? J Exp Clin Cancer Res CR 36:135.
   PubMed Web of Science ®Google Scholar
• Craparo EF, Sardo C, Serio R, et al. (2014). Galactosylated polymeric carriers for liver targeting of sorafenib. Int J Pharm 466:172–80.
   PubMed Web of Science ®Google Scholar
• Danhier F, Messaoudi K, Lemaire L, et al. (2015). Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. Int J Pharm 481:154–61.
   PubMed Web of Science ®Google Scholar
• Den RB, Kamrava M, Sheng Z, et al. (2013). A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 85:321–8.
   PubMed Web of Science ®Google Scholar
• Fellah S, Girard N, Chinot O, et al. (2011). Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. JCO 29:e308–11.
   PubMed Web of Science ®Google Scholar
• Gao DY, Lin TT, Sung YC, et al. (2015). CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials 67:194–203.
   PubMed Web of Science ®Google Scholar
• Grillone A, Riva ER, Mondini A, et al. (2015). Active targeting of sorafenib: preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles. Adv Healthc Mater 4:1681–90.
   PubMed Web of Science ®Google Scholar
• Hassler MR, Ackerl M, Flechl B, et al. (2014). Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study. Anticancer Drugs 25:723–8.
   PubMed Web of Science ®Google Scholar
• Heurtault B, Saulnier P, Pech B, et al. (2002). A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19:875–80.
   PubMed Web of Science ®Google Scholar
• Hirsjärvi S, Belloche C, Hindré F, et al. (2014). Tumour targeting of lipid nanocapsules grafted with cRGD peptides. Eur J Pharm Biopharm 87:152–9.
   PubMed Web of Science ®Google Scholar
• Hottinger AF, Aissa AB, Espeli V, et al. (2014). Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 110:2655–61.
   PubMed Web of Science ®Google Scholar
• Hureaux J, Lagarce F, Gagnadoux F, et al. (2009). The adaptation of lipid nanocapsule formulations for blood administration in animals. Int J Pharm 379:266–9.
   PubMed Web of Science ®Google Scholar
• Hureaux J, Lagarce F, Gagnadoux F, et al. (2010). Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. Pharm Res 27:421–30.
   PubMed Web of Science ®Google Scholar
• Huynh NT, Morille M, Bejaud J, et al. (2011). Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect. Pharm Res 28:3189–98.
   PubMed Web of Science ®Google Scholar
• Huynh NT, Passirani C, Allard-Vannier E, et al. (2012). Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. Int J Pharm 423:55–62.
   PubMed Web of Science ®Google Scholar
• Huynh NT, Passirani C, Saulnier P, et al. (2009). Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379:201–9.
   PubMed Web of Science ®Google Scholar
• Hwang SH, Cha J, Jo K, et al. (2015). Correlation of tumor size and metabolism with perfusion in hepatocellular carcinoma using dynamic contrast enhanced CT and F-18 FDG PET-CT. J Nucl Med 56:1330.
   Web of Science ®Google Scholar
• Jain RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62.
   PubMed Web of Science ®Google Scholar
• Jain RK. (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989.
   PubMed Web of Science ®Google Scholar
• Kallinowski F, Schlenger KH, Runkel S, et al. (1989). Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49:3759–3764.
   PubMed Web of Science ®Google Scholar
• Karim R, Palazzo C, Evrard B, et al. (2016). Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release 227:23–37.
   PubMed Web of Science ®Google Scholar
• Kober F, Iltis I, Izquierdo M, et al. (2004). High-resolution myocardial perfusion mapping in small animals in vivo by spin-labeling gradient-echo imaging. Magn Reson Med 51:62–67.
   PubMed Web of Science ®Google Scholar
• Lainé AL, Clavreul A, Rousseau A, et al. (2014). Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules. Nanomedicine Nanotechnol Biol Med 10:1667–1677.
   PubMed Web of Science ®Google Scholar
• Laine AL, Huynh NT, Clavreul A, et al. (2012). Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. Eur J Pharm Biopharm 81:690–693.
   PubMed Web of Science ®Google Scholar
• Le Roux G, Moche H, Nieto A, et al. (2017). Cytotoxicity and genotoxicity of lipid nanocapsules. Toxicol in Vitro 41:189–199.
   PubMed Web of Science ®Google Scholar
• Lee EQ, Kuhn J, Lamborn KR, et al. (2012). Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncol 14:1511–1518.
   PubMed Web of Science ®Google Scholar
• Lemaire L, Nel J, Franconi F, et al. (2016). Perfluorocarbon-loaded lipid nanocapsules to assess the dependence of U87-human glioblastoma tumor pO2 on in vitro expansion conditions. PloS One 11:e0165479
   PubMed Web of Science ®Google Scholar
• Li YJ, Dong M, Kong FM, et al. (2015). Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics. Int J Pharm 489:83–90.
   PubMed Web of Science ®Google Scholar
• Lin L, Cai J, Jiang C. (2017). Recent advances in targeted therapy for glioma. Curr Med Chem 24:1365–1381.
   PubMed Web of Science ®Google Scholar
• Lin TT, Gao DY, Liu YC, et al. (2016). Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. J Control Release 221:62–70.
   PubMed Web of Science ®Google Scholar
• Liu J, Boonkaew B, Arora J, et al. (2015). Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma. J Pharm Sci 104:1187–1196.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang J, Wang X, et al. (2016). In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid)-cystamine hydrochloride-D-α-tocopherol succinate. J Biomater Sci Polym Ed 27:1729–1747.
   PubMed Web of Science ®Google Scholar
• Lollo G, Vincent M, Ullio-Gamboa G, et al. (2015). Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm 495:972–980.
   PubMed Web of Science ®Google Scholar
• Ma J, Li S, Reed K, et al. (2003). Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 305:833–839.
   PubMed Web of Science ®Google Scholar
• Miller JJ, Wen PY. (2016). Emerging targeted therapies for glioma. Expert Opin Emerg Drugs 21:441–452.
   PubMed Web of Science ®Google Scholar
• Mo L, Song JG, Lee H, et al. (2018). PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. Nanomedicine Nanotechnol Biol Med 14:557–567.
   PubMed Web of Science ®Google Scholar
• Navis AC, Bourgonje A, Wesseling P, et al. (2013). Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PloS One 8:e58262
   PubMed Web of Science ®Google Scholar
• Ndesendo M. (2015). Advances in neurotherapeutic delivery technologies. OMICS International https://doi.org/10.4172/978-1-63278-036-2-037
   Google Scholar
• Peereboom DM, Ahluwalia MS, Ye X, et al. (2013). NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncology 15:490–496.
   PubMed Web of Science ®Google Scholar
• Rajendran R, Huang W, Tang AMY, et al. (2014). Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI. Cancer Med 3:47–60.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Vredenburgh JJ, Desjardins A, et al. (2011). Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101:57–66.
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Benoit JP. (2011). Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm 79:181–188.
   PubMed Web of Science ®Google Scholar
• Roger M, Clavreul A, Venier-Julienne MC, et al. (2011). The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 32:2106–2116.
   PubMed Web of Science ®Google Scholar
• Saliou B, Thomas O, Lautram N, et al. (2013). Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide. Eur J Pharm Sci 50:172–180.
   PubMed Web of Science ®Google Scholar
• Séhédic D, Chourpa I, Tétaud C, et al. (2017). Locoregional confinement and major clinical benefit of 188Re-Loaded CXCR4-targeted nanocarriers in an orthotopic human to mouse model of glioblastoma. Theranostics 7:4517–4536.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Raskett CM, Gilbert CA, et al. (2010). Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett 478:165–170.
   PubMed Web of Science ®Google Scholar
• Silva AC, Kim SG, Garwood M. (2000). Imaging blood flow in brain tumors using arterial spin labeling. Magn Reson Med 44:169–173.
   PubMed Web of Science ®Google Scholar
• Sorensen AG, Emblem KE, Polaskova P, et al. (2012). Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72:402–407.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996.
   PubMed Web of Science ®Google Scholar
• Sun Y, Schmidt NO, Schmidt K, et al. (2004). Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med 51:893–899.
   PubMed Web of Science ®Google Scholar
• Towner RA, Ihnat M, Saunders D, et al. (2015). A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model. BMC Cancer 15:522
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Lacoeuille F, Belloche C, et al. (2011). Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)re-lipid nanocapsules. Biomaterials 32:6781–6790.
   PubMed Web of Science ®Google Scholar
• Vinchon-Petit S, Jarnet D, Paillard A, et al. (2010). In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. J Neurooncol 97:195–205.
   PubMed Web of Science ®Google Scholar
• Wang W, Sivakumar W, Torres S, et al. (2015). Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurg Focus 38:E8
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Liu Y, Yang S, et al. (2016). Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids Surf B Biointerfaces 141:83–92.
   PubMed Web of Science ®Google Scholar
• Yang F, Brown C, Buettner R, et al. (2010). Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther 9:953–962.
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang B, Gong X, et al. (2016). In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. Int J Nanomedicine 11:2329–2343.
   PubMed Web of Science ®Google Scholar
• Yang YC, Cai J, Yin J, et al. (2016). Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers. Carbohydr Polym 136:782–790.
   PubMed Web of Science ®Google Scholar
• Yun TJ, Cho HR, Choi SH, et al. (2016). Antiangiogenic effect of bevacizumab: Application of arterial spin-labeling perfusion MR imaging in a rat glioblastoma model. AJNR Am J Neuroradiol 37:1650–1656.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu J, Chan HF, et al. (2016). iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Nanomedicine Nanotechnol Biol Me 12:1303–1311.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang T, Mu S, et al. (2017). Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. Nanomed 12:911–925.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gong F, Zhang F, et al. (2013). Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int J Nanomedicine 8:1517–1524.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Niu B, Chen J, et al. (2014). The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. Biomaterials 35:4565–4572.
   PubMed Web of Science ®Google Scholar
• Ziegler J, Bastian A, Lerner M, et al. (2017). AG488 as a therapy against gliomas. Oncotarget 8:71833–71844.
   PubMedGoogle Scholar
• Zustovich F, Landi L, Lombardi G, et al. (2013). Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res 33:3487–3494.
   PubMed Web of Science ®Google Scholar